You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
NEW YORK – CAR T cells that target both CD19 and CD20 antigens on the surface of B cells in hematologic malignancies may be a promising strategy to avoid relapse and resistance, a recently published Phase I study has shown.
Premium Access gives you: ✔ Full site access ✔ Interest-based email alerts ✔ Access to archives
Never miss another important industry story.
Try Premium Access now.
You may already have institutional access!
Check if I qualify.
Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
The Phosphoinositide 3-Kinase (PI3K) pathway is one of the most frequently altered pathways in human cancer and plays a significant role in disease progression and resistance to endocrine therapy.